1-7 of 7
Ranjana H. Advani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Singh Cheema, Philip A. Dy, Timothy E. O'Brien, Jane N. Winter, Terrence P. Cescon, Julie E. Chang, Brad S. Kahl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4468–4477.
https://doi.org/10.1158/1078-0432.CCR-20-1345
Published: 01 September 2020
View article titled, A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Open the PDF for A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1718–1726.
https://doi.org/10.1158/1078-0432.CCR-18-2435
Published: 15 March 2019
View article titled, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Open the PDF for Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Ranjana H. Advani, Daniel Lebovic, Andy Chen, Mark Brunvand, Andre Goy, Julie E. Chang, Ephraim Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Priya Agarwal, Randall C. Dere, Hsin-Ju Hsieh, Surai Jones, Yu-Waye Chu, Bruce D. Cheson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (5): 1167–1176.
https://doi.org/10.1158/1078-0432.CCR-16-0772
Published: 28 February 2017
View article titled, Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Open the PDF for Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment

Andrew J. Gentles, Ash A. Alizadeh, Alvaro J. Alencar, Holbrook E. Kohrt, Roch Houot, Matthew J. Goldstein, Yasodha Natkunam, Ranjana H. Advani, Randy D. Gascoyne, Javier Briones, Sylvia K. Plevritis, Izidore S. Lossos, Ronald Levy
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): PR5.
https://doi.org/10.1158/1078-0432.TCMUSA10-PR5
Published: 02 February 2016
View article titled, Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment
Journal Articles

Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.

Italo Poggesi, Maria Luisa Sardu, Eleonora Marostica, Juthamas Sukbuntherng, Betty Y. Chang, Jan de Jong, Xavier Woot de Trixhe, An Vermeulen, Giuseppe De Nicolao, Susan Mary O'Brien, John C Byrd, Ranjana H Advani, Danelle Frances James, William Deraedt, Darrin Beaupre, Michael Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): B19.
https://doi.org/10.1158/1557-3265.HEMMAL14-B19
Published: 19 August 2015
View article titled, Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.
Journal Articles

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, Nancy L. Bartlett
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 248–255.
https://doi.org/10.1158/1078-0432.CCR-11-1425
Published: 02 January 2012
View article titled, A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Open the PDF for A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Ranjana H. Advani, Herbert I. Hurwitz, Michael S. Gordon, Scot W. Ebbinghaus, David S. Mendelson, Heather A. Wakelee, Ute Hoch, Jeffrey A. Silverman, Nancy A. Havrilla, Craig J. Berman, Judith A. Fox, Roberta S. Allen, Daniel C. Adelman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2167–2175.
https://doi.org/10.1158/1078-0432.CCR-09-2236
Published: 31 March 2010
View article titled, Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Open the PDF for Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules in another window